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Patients with residual diseases (RD) usually have poor prognoses after standard neoadjuvant 
chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant 
treatments for patients with RD after standard neoadjuvant chemotherapy, and found therapeutic targets 





Purpose: Patients with residual diseases (RD) usually have poor prognoses after neoadjuvant 
chemotherapy for breast cancer. The aim of this study was to explore therapeutic targets and potential 
additional adjuvant treatments for patients with RD after standard neoadjuvant chemotherapy.  
Materials and Methods: We retrieved publicly available cDNA microarray data from 399 human 
epidermal growth factor 2 negative primary breast cancer samples from patients undergone standard 
neoadjuvant chemotherapy. We analyzed the mRNA expression levels of key breast cancer markers and 
therapeutic target genes based on residual cancer burden (RCB) classification: RCB-0/I, RCB-II, and 
RCB-III. 
Results: Among hormone receptor (HR) -positive samples, there were more luminal A tumors by PAM50 
in RCB-III than in RCB-0/I and RCB-II (P < 0.01). The mRNA expressions of ESR1 and PGR were 
significantly higher and that of MKI67 was lower in RCB-II and RCB-III than in RCB-0/I. The mRNA 
expression of cyclin D1 was upregulated in RCB-III and that of CDKN2A was down-regulated in RCB-III 
(P = 0.027 and < 0.01). Among triple negative (TN) samples, RCB-III had higher clinical Stage and more 
lymph node-positive samples than RCB-0/1 and RCB-II (P < 0.01). In both subtypes, VEGF-C 
expression was significantly higher in RCB-III than in RCB-0/I and RCB-II. 
Conclusion: In HR-positive breast cancer, biological features such as luminal A were associated with 
RCB; this trend was not observed in TN breast cancer. Further, some targeted therapies should be tested 




Neoadjuvant chemotherapy has become a standard treatment option for breast cancer 1.  Apart from 
reducing tumor size and increasing the rate of breast-conserving surgeries, it also allows us to assess the 
response of the patient to systemic treatment. Furthermore, neoadjuvant therapy is an important strategy 
for drug development and identification of predictive biomarkers2. Clinical trials in neoadjuvant settings 
are increasingly being conducted for breast cancer; however, discovering new agents and novel 
therapeutic strategies in adjuvant settings could incur high costs and are highly time-consuming3. 
 Neoadjuvant trials can help discover novel predictive biomarkers that can be validated by additional 
studies in neoadjuvant and adjuvant settings before being adopted for clinical practice 3. Neoadjuvant 
trials can also be utilized to test the efficacy of biomarker-driven targeted therapies against different 
breast cancer subtypes 3. 
The pathological complete response (pCR) after neoadjuvant chemotherapy is an important prognostic 
factor and a surrogate maker for long-term outcome in patients with primary breast cancer4, 5. Previous 
studies have shown that patients who achieved pCR after neoadjuvant chemotherapy had better prognoses 
in specific intrinsic subtypes, especially triple negative (TN) and human epidermal growth factor 2 
(HER2)-positive breast cancer 5. Patients with TN breast cancers who achieved pCR had excellent 
survival, while those who did not achieve pCR after neoadjuvant chemotherapy had significantly shorter 
overall and post-recurrence survival; more than 30% of recurrent patients with residual diseases had an 
overall survival (OS) of 3 years 6. 
Previous meta-analyses have shown that pCR is not a suitable surrogate marker for long-term prognosis 
in hormone receptor (HR)-positive and HER2-negative subtypes; other potential surrogate markers 
should therefore be investigated for HR-positive breast cancer 7. In cases that have not achieved pCR, the 
combination of residual tumor size, tumor cellularity and nodal status after neoadjuvant treatment is 
prognostic 8.  Symmans et al. introduced a measure called residual cancer burden (RCB), a continuous 
variable derived from the largest area and cellularity of residual invasive primary cancer, the number of 
involved lymph nodes, and the size of the largest metastasis 8. They divided all tumors observed after 
neoadjuvant chemotherapy into four classes based on predefined cut points of 1.36 and 3.28 index scores: 
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pCR (stage yp-T0/is, ypN0; RCB = 0), minimal RCB (RCB-I), moderate RCB (RCB-II), and extensive 
RCB (RCB-III) 8, 9. The pathological response to neoadjuvant chemotherapy based on RCB scores and 
classes is prognostic for all phenotypic subtypes of breast cancer, including HR-positive, HER2-positive, 
and TN 9. For subgroups that have poorer prognoses and show residual breast cancer after standard 
neoadjuvant treatment, additional new treatment strategies are needed. 
 Several clinical trials have been conducted to evaluate the efficacy of adjuvant chemotherapy or targeted 
therapy for patients with residual breast cancer after standard neoadjuvant chemotherapy 10. Masuda et al. 
reported the results of the Capecitabine for Residual Cancer as Adjuvant Therapy (CREATE-X) trial, a 
multi-center, open-label, randomized, phase-3 trial designed to evaluate the efficacy and safety of 
adjuvant capecitabine monotherapy in patients with HER2-negative primary breast cancer, who 
developed residual invasive diseases after standard neoadjuvant chemotherapy with anthracycline, taxane, 
or both 10. Adjuvant capecitabine therapy was found to prolong disease-free survival (DFS) and OS 
among these patients. Capecitabine is therefore an effective adjuvant option in these patients 10. It is still 
unclear whether there are other suitable candidates for additional adjuvant treatment agents. 
The aim of this study was to explore therapeutic targets for patients with residual breast cancer based on 
RCB classes and to investigate other potential adjuvant treatments after standard neoadjuvant 
chemotherapy for subgroups with poor prognoses. We also performed functional analyses of the 
properties of RCB. 
 
Materials and methods 
Patients and cohort 
We retrieved publicly available cDNA microarray data from 508 primary breast cancer samples (all 
patients with those samples had received anthracycline and taxane-based neoadjuvant chemotherapy from 
NCBI Gene Expression Omnibus [GEO] repository [https://www.ncbi.nlm.nih.gov/geo/] GSE 25066) 
11.The cDNA microarray data were corrected from tumor biopsy samples prior to any systemic therapy11. 
ER and PR status were assessed using immunohistochemistry (IHC) (6F11; Novocastra Laboratories 
Ltd., Newcastle, UK). The cutoff for ER positivity and PR positivity was set at 10% positive tumor cells 
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after nuclear staining. Pathological HER2 positivity was defined as IHC (Dako North America Inc., 
Carpinteria, CA) staining of 3+ and/or amplification of HER2 gene copy number by fluorescent in situ 
hybridization (FISH) based on American Society of Clinical Oncology / College of American 
Pathologists guidelines 11, 12. From the 508 samples retrieved, we excluded 109 HER2-positive samples, 
and the remaining 399 were analyzed. HR-positive breast cancer was defined as ER- and/or PR-positive, 
and HER2-negative and TN breast cancers were defined as ER-, PR-, and HER2-negative. All HR-
positive patients received adjuvant hormone therapy. Clinical nodal status was determined before 
treatment through physical examination with or without axillary ultrasound and diagnostic fine-needle 
aspiration, as required 11. The clinical and pathological characteristics for the cohort studied are shown in 
Online appendix 1. 
 This data was annotated using the Affymetrix Human Genome Array (Affymetrix Inc., Santa Clara, CA). 
All gene expression data were generated using Affymetrix gene chips and normalized using the Mas5 
algorithm (http://www.bioconductor.org) with log 2 transformation.  
 All 399 breast cancer samples were stratified into three groups based on the RCB classification system: 
RCB-0/I, RCB-II, and RCB-III.   
 
Gene expression analysis 
First, we compared the mRNA expression levels of four well-established breast cancer markers: ESR1, 
PGR, ERBB2, and MKI67. To evaluate the associations between RCB classes and gene expression levels, 
we used the Wilcoxon rank sum test to distinguish between all the pairs of RCB groups and the Kruskal–
Wallis rank sum test to distinguish between the three RCB groups. 
Second, we selected 41 genes that are targeted by FDA-approved drugs or have been investigated with 
clinical trials as molecular target agents for different malignant tumors, including breast cancer, to 
explore additional novel adjuvant therapies for breast cancer patients with poor prognosis after 
neoadjuvant chemotherapy. The information on anticancer therapy drugs was obtained from National 
Cancer Institute (NCI) drug information 13, Drug@FDA 14, and Clinical Trials gov  15, 16. 
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Some of the 41 selected genes were associated with breast cancer (AR, ERBB3, and p53), DNA damage 
repair pathways and BRCA functions (BRCA1, BRCA2, PARP1, and PARP2), cyclin dependent kinase 
(CDK) pathway (CDK2, CDK4, CDK6, CCND1, CDKN2A, and RB1), vascular endothelial growth factor 
(VEGF) and VEGF receptor pathways (VEGF-A, VEGF-B, VEGF-C, EGFR, PGF, KDR, and FTL4), 
modulation of DNA methylation and histone acetylation (HDAC1, HDAC2, HDAC3, DNMT1, DNMT3A, 
and DNMT3B), immune responses (PDCD1LG2), and mTOR pathway (mTOR, PIK3CA). Others were 
used in FDA-approved drugs or under investigated for cancers other than breast cancer (AKT1, ALK, 
RAF1, CTNNB1, MET, STK11, PTEN, NF1, ROS1, NOTCH1, ATM, KITL, and KRAS). 
We used the Wilcoxon rank sum test and the Kruskal-Wallis rank sum test to evaluate the associations 
between RCB classes and gene expression levels in the different breast cancer subtypes. 
All statistical analyses were performed using the BRB Array Tools software (version 4.5.1; 
http://linus.nci.nih.gov/BRB-ArrayTools.html) and R software (version 3.4.1; http://www.r-project.org). 
Differences with two-sided P values ≤ 0.05 were considered statistically significant.  This was 
retrospective study from the public database and there was no need for ethical approval by the 




We analyzed previously published gene expression data of 399 breast cancer samples obtained from 
Hatzis et al. (available at GSE 25066) and classified them based on their RCB classification 11. Clinical 
and pathological characteristics of the samples are shown in Table 1 and Online appendix 1. Among the 
399 samples, 206 (52%) were lymph node-positive, 168 (42%) were cStage III, 204 (51%) were 
histological grade III, and 253 (63%) were HR-positive. For the HR-positive samples, the different RCB 
subgroups had significantly different clinical nodal status, cStage before neoadjuvant chemotherapy, ER 
IHC status, and PAM50 classification (P = 0.045, 0.0068 and <0.001, respectively). As shown in Table 1, 
among the HR-positive cases, RCB-0/I tumors were of significantly higher nuclear and histological grade 
than RCB-III tumors (P = 0.0049); there were more luminal A tumors in RCB-III than in RCB-0/1 and 
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RCB-II (63% and 22%, respectively). The rate of clinical node-negative tumors was higher in RCB-III 
than in RCB-0/I and RCB-II (P < 0.001) (Table 1). Thus, tumors that are node-negative and show low 
proliferation rate may be associated with RCB-III and poor prognosis.  
In contrast, for TN breast cancer samples, only clinical nodal status (P = 0.0053) and cStage (P = 0.0029) 
were significantly different among the RCB groups; as expected, RCB III had more cStage and lymph 
node-positive tumors than the other groups (Table 1). 
 
Gene expression analysis of four well-established breast cancer markers according to RCB 
subclasses 
To explore the associations between RCB subclasses and expression levels of well-established breast 
cancer markers, we deduced the mRNA gene expression levels of ESR1, PGR, ERBB2, and MKI67 
separately by hormone receptor status.  
Hormone receptor-positive breast cancer 
The mRNA expression levels of ESR1 and PGR were significantly higher in RCB-II and RCB-III tumors 
than in RCB-0/I tumors (P = 0.00053 and P = 0.0061, respectively) (Figure 1). However, the expression 
level of MKI67 was lower in RCB-III than in RCB-0/I and RCB-II, while that of ERBB2 was not 
significantly different between the RCB groups.  
Triple negative breast cancer 
The mRNA expression level of ESR1 was higher in RCB-III tumors than in RCB-I and RCB-II tumors, 
although the average expression level in all subgroups were lower than those in ER-positive tumors 
(Figure 1). In our previous study, we found ESR1 mRNA > 10.18 and ERBB2 mRNA > 12.54, and both 
were defined as ER- and HER2-positive 17. The expression levels of PGR, ERBB2, and MKI67 were not 
significantly different between the RCB subgroups.  
 
Gene expression analysis of 41 molecular target markers according to RCB subclasses 
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Next, we analyzed 41 molecular target markers according to RCB subclasses with the aim of seeking 
novel drug targets suitable for use in cases with poor prognosis after standard neoadjuvant chemotherapy. 
The 41 selected genes are listed in Online appendix 2. 
Hormone receptor-positive breast cancer 
We found that the mRNA expression level of cyclin D1 (CCND1) was significantly upregulated in RCB-
III (P = 0.027), while those of CDKN2A (P = 0.0047) were significantly down-regulated in RCB-III. 
(Figure 2) We also observed upregulated VEGF-C expression in RCB-III, although other VEGF- and 
VEGF-R-related genes were not significantly upregulated in RCB-III (Figure 3). 
In RCB-0/I, DNMT1 and DNMT3A mRNAs were significantly overexpressed (P < 0.0001 and P = 
0.014, respectively). However, the expression levels of DNMT3B and HDAC family genes were not 
significantly different between the three RCB subgroups (Online appendix 3). 
No other genes showed significant differences in their expression levels between RCB subgroups in the 
HR-positive samples. 
Triple negative breast cancer  
The expression level of VEGF-C was higher in RCB-III than in RCB-0/I and RCB-II (P = 0.029) (Figure 
3). We found also that the mRNA expression level of CDKN2A (P = 0.044) were significantly down-
regulated in RCB-III, however the difference was smaller than that shown in  hormone receptor positive 
tumors (Figure2).DNMT3A was also upregulated in RCB-0/I than RCB-II (P = 0.039), although there 
was no difference in the expression levels of DNMT1 and DNMT3B between the RCB subgroups 
(Online appendix 3). No other genes showed significant differences in their expression levels between the 
different RCB subgroups in TN breast cancer samples.  
 
Discussions  
 The RCB scoring system could be a reliable prognostic marker after neoadjuvant chemotherapy; RCB-III 
breast cancers after neoadjuvant chemotherapy show poor prognosis, regardless of hormone receptor 
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status 8, 9. RCB-III breast cancers show poor outcomes despite favorable outcomes for most other HR-
positive cancers 9.  In this study, we analyzed the relationship between poor prognoses and expression of 
candidate target genes; we also explored additional targeted therapies to improve prognosis after standard 
neoadjuvant chemotherapy. 
First, we found that luminal A-like cases with higher clinical stages had poorer prognosis than luminal B, 
indicating that some luminal A-like cases might have poorer responses to chemotherapy. We next focused 
on pathological background features and the expression levels of four established breast cancer marker 
genes: ESR1, PGR, ERBB2, and MKI67. Among HR-positive samples, RCB-III contained more tumors 
with low proliferation characteristics, low expression of MKI67, high expression of PGR, luminal A by 
PAM 50 than RCB-0/I and RCB-II (Table 1). This was an interesting result, as Symmans et al. had shown 
that RCB score was a prognostic marker and RCB-III tumors have poor prognoses 8, 9, although previous 
studies had shown that luminal A-like tumors have excellent prognoses 18. It is understood that luminal A 
tumors generally have better prognosis, while a small population of RCB-III tumors have poorer 
prognoses and may be resistant to chemotherapy and hormone therapy. These results were also supported 
by a previous study that used the same dataset (GSE25066), in which Symmans et al. showed that most 
RCB-III tumors were also resistant to hormone therapy 19. Thus, our results suggest that RCB-III tumors 
show poor prognoses due to resistance to treatment, despite most of them being luminal-A tumors. Such 
HR-positive cases that show resistance to chemotherapy and hormone therapy should be tested with 
additional treatment strategies. In contrast, for TN breast cancers, there was no significant difference in 
the expression levels of the four marker genes between the RCB subgroups; however, there were more 
tumors of higher clinical stage and nodal metastasis in RCB-III than in RCB-I and RCB-II. (Table 1) Our 
results suggest that the clinical stage of the tumor influences the effectiveness of chemotherapy more than 
biological features (e.g., ER, PR, HER2 and Ki67) for the TN breast cancers, but not HR-positive ones. 
HR-positive breast cancers show better prognoses than HER2-positive or TN ones. Our results suggest 
that cyclin-dependent kinase inhibitors may be suitable therapeutic targets for RCB-III HR-positive breast 
cancers after standard neoadjuvant chemotherapy. A cyclin-dependent kinase inhibitor, palbociclib, was 
recently approved around the world, based on the results of PALOMA-1, PALOMA-2, and PALOMA-3 
trials for metastatic HR-positive and HER2-negative breast cancer. Based on a previous in vitro study, it 
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was hypothesized that the expression levels of Cyclin D1 and p16 are related to the response to 
palbociclib 20. We found that the CCND1 (cyclin D1) mRNA was overexpressed in RCB-III tumors, 
while the CDKN2A mRNA was under-expressed (Figure 2).  However, in the PALOMA-1 trial, a subset 
of patients with CCND1 amplification was assessed, and no difference was observed between patients 
with and without such amplification 21. Further, in PALOMA-2, no differential benefit was observed in 
the palbociclib treatment group, whose tumors showed different expression levels of Cyclin D1 and p16 
through immune-histochemical staining 22. Nevertheless, it must be noted that immunohistochemistry is 
not accurate enough to assess the expression level of CCND1, and we suggest that assessing mRNA 
levels within tumors might provide more accurate perception. Therefore, the role of CCND1 
amplification and/or loss of p16 in patient selection remains unclear and need to be studied further 23. The 
German Breast Group and the International Collaborating Breast Cancer Group launched a study called A 
Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 
Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery (PENELOPE-B). 
PENELOPE-B is designed to demonstrate that, with background standard endocrine therapy, palbociclib 
can provide superior invasive disease-free survival in pre- and postmenopausal women with HR-
positive/HER2-negative early breast cancer who are at high risk of relapse after showing less than pCR to 
neoadjuvant therapy with taxane. We believe that the results of the PENELOPE-B trial will confirm the 
utility of palbociclib as adjuvant therapy for patients with residual tumor and poor prognosis after 
neoadjuvant chemotherapy. 
Remarkably, the expression of CCND1 was not different between the RCB subgroups among TN breast 
cancers, although CDKN2A was over expressed in RCB-0/I compared to RCB-II and RCB-III (Figure 1). 
This was contrary to the results obtained for HR-positive tumors. The role of CDKN2A (p16) in TN 
breast cancer has been studied 24. Arima et al. reported that a lack of p16 expression is associated with a 
reduced response of tumors to chemotherapy, possibly because of the acquisition of cancer stem cell-like 
properties; they also showed that downregulation of p16 expression is a marker for poor response to some 
chemotherapeutic agents and an aggressive phenotype in TN breast cancer 24. These results support our 
observation of low CDKN2A expression in RCB-III (Figure 2). 
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In both HR-positive and TN breast cancers, VEGF-C was found to be overexpressed in RCB-III 
compared to RCB-0/I and RCB-II (Figure 2). VEGF-C has been identified as a multifaceted factor 
involved in the regulation of tumor angiogenesis and lymphangiogenesis 25. Previous reports have shown 
that VEGF-C is overexpressed in breast cancer specimens compared to adjacent normal mammary glands, 
indicating a significant correlation with lymphatic vessel invasion and survival rate 26.  The binding 
partners of VEGF-C are two tyrosine kinase receptors, VEGFR2 (or KDR/FLK1) and VEGFR3 (or 
FLT4) 26. 
Our results showed an overexpression of VEGF-C in RCB-III compared to RCB-0/I and RCB-II for 
both cancer subtypes, which is consistent with previous findings of associations between VEGF-C and 
lymphangiogenesis. Thus, our results indicate that VEGF-C may be an additional therapeutic target; 
however, monoclonal antibodies of VEGF-C are still relatively poorly studied. Multi-tyrosine kinase 
inhibitors, including monoclonal antibodies of VEGF-C, may be suitable therapeutic targets, although 
further studies are needed before practical use is possible. This would confirm the validity of our strategy 
of selecting candidate genes from deposited data after neoadjuvant chemotherapy 27.  
We also found that DNMT1 and DNMT3A were significantly overexpressed in RCB-0/I (Online appendix 
3). Among HR-positive breast cancer samples, we observed high expression levels of DNMT1 and 
DNMT3A in RCB-0/I; we also found more node-positive patients in RCB-0/I (51%) than in RCB-II 
(36%) and more IHC ER-positive tumors (64%) in RCB-0/I than in RCB-II or RCB-III (Table 1). These 
results are supported by previous studies that showed that DNMT1 is significantly correlated with lymph 
node metastasis and that DNMT1 and DNMT3A are correlated with promoter hypermethylation and 
reduced expression of ER α28-30. Thus, for non-luminal A-like HR-positive RCB-0/1 tumors, anti-DNMT 
inhibitors may be suitable therapeutic candidates after neoadjuvant chemotherapy (Table 1).  For TN 
cancers, DNMT1 and DNMT3A expression levels did not differ between RCB subgroups. 
 This study had several limitations, which could be overcome by performing additional tests. First, the 
sample sizes for both HR-positive and TN breast cancers were relatively small in each RCB subgroup. 
Second, we should perform variation testing for another cohort classified by RCB scores to confirm our 
results. Third, preparing different datasets may increase the reproducibility of our results. Fourth, RCB 
scores should be calculated after neoadjuvant chemotherapy, regardless of whether chemotherapy is 
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needed or not. Finally, for some HR-positive cases, receiving chemotherapy might have led to over-
treatment with little or no benefit. Despite these limitations, our observations are consistent with the 
hypothesis that the expression levels of some target genes were higher in RCB-III after standard 
neoadjuvant therapy; our results also support those of previous clinical and preclinical studies. We have 
identified some therapeutic targets that may be candidates for additional treatment. Further studies will be 




We found a relationship between mRNA gene expression pattern and the response of patients to 
chemotherapy by ER status. We have also identified some candidate targets that may be suitable for 
therapeutic strategies after standard neoadjuvant chemotherapy. We will explore therapeutic strategies for 
other situations using the same strategy in future studies. 
 
 
Clinical Practice Points 
l There was distinct gene expression pattern depending on degrees of efficacy after neoadjuvant 
chemotherapy by ER status.   
 
l Distinct therapeutic targets by ER status may be candidate as additional adjuvant therapeutic options 
except one gene, VEGF-C. 
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Figure 1. mRNA expression level of known subtype specific prognostic biomarker according to residual 
cancer burden (RCB) score in ER and/or PR positive and triple negative breast cancer.   
Box plots indicate 1st and 3rd quartiles and the bold line within the box represents the median value of 
log2-normalized mRNA expression levels. The outliers are defined by the R statistical package as data 
points that fall outside the 1st and 3rd quartiles by more than 1.5 times the interquartile range, and circles 
falling outside the box represent outliers. The p values were calculated from the Kruskal-Wallis 
nonparametric test or the Wilcox test comparing the differences between all three or two RCB subgroups, 
based on RCB scores. Boxplots of a; ESR1 (Probe 205225_at), b; PR (Probe 208305_at), c; ERBB2 
(Probe 216836_s_at), d; MKi67 (Probe 212021_s_at). 
 
Figure 2. mRNA expression levels of CDK4/6/cyclin D1 complex-related genes according to RCB scores 
in ER- and/or PR-positive and triple negative breast cancer.  
The median ± S.D. values of log2-normalized mRNA expression levels are plotted on the y-axis, as 
described in Fig. 1 legend. The p values were calculated from the Kruskal-Wallis nonparametric test or 
the Wilcox test comparing the differences between all three or two RCB subgroups based on the RCB 
scores. Boxplots of a; CCND1 (cyclin D1) (Probe 208712_at), b; CDKN2A (Probe 209644_x_at). 
 
Figure 3. mRNA expression levels of genes related to VEGF-C (Probe 209946_at) according to RCB 
scores in ER- and/or PR-positive and triple negative breast cancer. The median ± S.D. values of log2-
normalized mRNA expression levels are plotted on the y-axis, as described in the legend for Fig. 1. The p 
values were calculated from the Kruskal-Wallis nonparametric test or the Wilcox test comparing the 







RCB Index 0/I II III Total 0/I II III
Number % Number % Number % Number % p value Number % Number % Number % % p value
53 21 135 53 65 26 253 63 60 41 46 32 40 27 37
Age,years
<50 25 47 71 53 35 54 131 52 0.76 36 60 27 59 18 45 55 0.31
≥50 28 53 64 47 30 46 122 48 24 40 19 41 22 55 45
median 51 50 49 50 48 47.5 51
clinical Tstage
cT0 1 21 2 1 0 0 3 1 0.15 0 0 0 0 0 0 0 0.013
cT1 4 8 10 7 2 3 16 6 6 10 1 2 0 0 5
cT2 29 55 75 56 37 57 141 56 36 60 21 46 15 38 49
cT3 13 25 30 22 8 12 51 2 11 18 16 35 10 25 25
cT4 6 11 18 13 18 28 42 17 7 12 8 17 15 38 21
Positive 27 51 53 39 12 18 92 36 < 0.001 43 72 33 72 38 95 78 0.0053
Negative 26 49 82 61 53 82 161 64 17 28 13 28 2 5 22
0 0 0 0 0 0 0 0 0 0.045 0 0 0 0 0 0 0 0.0029
I 2 47 2 1 0 0 4 2 3 5 0 0 0 0 2
II 32 6 86 64 30 46 148 58 33 55 23 50 10 25 45
III 19 36 47 35 35 54 101 40 24 40 23 50 30 75 53
Grade
1 2 4 16 12 8 12 26 10 0.0049 0 0 1 2 0 0 1 0.14
2 17 32 75 56 36 55 128 51 4 7 8 17 6 15 12
3 30 57 40 30 19 29 89 35 52 87 35 76 28 70 79
NA 4 8 4 3 2 3 10 4 4 7 2 4 6 15 8
ER IHC status
Positive 46 87 132 98 63 97 241 95 0.0068 0 0 0 0 0 0 0 1
Negative 7 13 3 2 2 3 12 5 60 1 46 1 40 1 1
PR IHC status
Positive 34 64 106 79 50 77 190 75 0.12 0 0 0 0 0 0 0 1
Negative 19 36 29 21 15 23 63 25 60 1 46 1 40 1 1
PAM50
LuminalA 12 23 74 55 41 63 127 50 < 0.001 0 0 2 4 0 0 1 0.32
LuminalB 13 25 29 21 14 22 56 22 0 0 2 4 1 3 2
HER2 5 9 10 7 4 6 19 8 4 7 3 7 5 13 8
Basal 17 32 11 8 4 6 32 13 50 83 32 70 31 78 77























Table1. Clinical and Pathologic Characteristics of all Patients. Fisher's exact test was used for between-group comparisons for this data.
Triple negative (N = 146)Hormone receptor positive (N = 253)
113
16
3
12
2
146
0
0
146
12
